PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
72.43
+0.73 (1.02%)
Apr 17, 2026, 4:00 PM EDT - Market closed
PTC Therapeutics Revenue
In the year 2025, PTC Therapeutics had annual revenue of $1.73B with 114.51% growth. PTC Therapeutics had revenue of $164.68M in the quarter ending December 31, 2025, a decrease of -22.75%.
Revenue (ttm)
$1.73B
Revenue Growth
+114.51%
P/S Ratio
3.46
Revenue / Employee
$1,746,372
Employees
991
Market Cap
6.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73B | 923.88M | 114.51% |
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
| Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
| Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
| Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
| Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
| Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
| Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
| Dec 31, 2011 | 105.41M | 100.45M | 2,022.34% |
| Dec 31, 2005 | 4.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 4.04M |
PTCT News
- 2 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 25 days ago - PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors - PRNewsWire
- 7 weeks ago - PTC Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 2 months ago - PTC Therapeutics Provides Regulatory Update on Translarna™ - PRNewsWire
- 2 months ago - PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 - PRNewsWire
- 3 months ago - PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - PRNewsWire
- 4 months ago - PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - PRNewsWire